Dana-Farber Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dana-Farber Cancer Institute sits in the top decile of US sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count).
Dana-Farber Cancer Institute: 781 sponsored US clinical trials, 112 recruiting.
Dana-Farber Cancer Institute sponsors 781 registered US clinical trials on ClinicalTrials.gov, 112 of them currently recruiting, and 449 completed. 15 of these trials are in Phase 3-4 (later-stage) and 492 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 53 trials.
Top-decile sponsor footprint
Dana-Farber Cancer Institute ranks in the top decile of sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
449 of 537 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
781 total, page 14 of 16
Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer
NCT00165568
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
NCT00126191
Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer
NCT00165334
Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant
NCT00376480
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
NCT00116142
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
NCT00400946
Computerized Assessment for Patients With Cancer
NCT00194493
Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine in Prostate Cancer Patients
NCT00139204
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
NCT00119730
Mifepristone (RU-486) in Androgen Independent Prostate Cancer
NCT00140478
Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer
NCT00116506
Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma
NCT00258687
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
NCT00357500
Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors
NCT00137774
The PediQUEST Study: Evaluation of Pediatric Quality of Life and Evaluation of Symptoms Technology
NCT01838564
Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy
NCT00146536
Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer
NCT00148707
Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer
NCT00137761
Title XELOX FOR SALIVARY GLAND CANCERS
NCT00101075
Capecitabine in Women With Operable Breast Cancer
NCT00148720
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
NCT00142168
Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
NCT00095875
Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer
NCT00165490
Avastin and Taxotere for Esophagogastric Cancer
NCT00137813
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
NCT00153933
Preoperative Cisplatin in Early Stage Breast Cancer
NCT00148694
Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma
NCT00251394
Capecitabine For Nasopharyngeal Cancer
NCT00095901
GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies
NCT00426205
Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
NCT00146601
Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy
NCT00165204
Monitoring of Erythroid Lineage Specific Chimerism Following Allogeneic Hematopoietic Transplantation for Thalassemia Major
NCT00480506
Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate
NCT00165503
Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
NCT00153985
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
NCT00047281
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
NCT00165399
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
NCT00137826
Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease
NCT00136396
Dosimetric Analysis of Vaginal Cuff Brachytherapy in Endometrial Carcinoma
NCT00165126
Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate
NCT00165516
A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer
NCT00134706
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma
NCT00117156
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
NCT00142129
Protein Tyrosine Kinases (PTK) in Multiple Myeloma
NCT00165347
Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors
NCT00098514
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
NCT00153920
Effects of Exercise Intervention on Insulin Levels in Breast Cancer Survivors
NCT00153894
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
NCT00144677
Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)
NCT00809588
Tarceva and Capecitabine for Pancreatic Cancer
NCT00125021
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 181 |
| Phase 2 | 311 |
| Phase 3 | 14 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Dana-Farber Cancer Institute pipeline
112 recruiting of 781 indexed (14% open); 449 completed (57%).
Phase mix: 15 late (III/IV) vs 492 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (53 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dana-Farber Cancer Institute: open-pipeline peers nationwide
Peers matched on 781 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Dana-Farber Cancer Institute sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 781 trials (± recruiting share)
- University of California, San Diego · 775 trials · 18% recruiting
- University of Chicago · 796 trials · 20% recruiting
- Medical University of South Carolina · 755 trials · 19% recruiting
- University of Utah · 818 trials · 17% recruiting
Sponsors near 14% open enrollment (± trial volume)
- The Cleveland Clinic · 14% recruiting · 688 trials
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
Related
What to do with this Dana-Farber Cancer Institute page
781 registered trials is a research-attention snapshot, not an endorsement of Dana-Farber Cancer Institute or any single study.
- 112 of Dana-Farber Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Dana-Farber Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dana-Farber Cancer Institute pipeline card: 781 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.